
ARS Pharmaceuticals Investor Relations Material
Latest events

Q1 2025
ARS Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ARS Pharmaceuticals Inc
Access all reports
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for patients and caregivers affected by severe allergic reactions, including anaphylaxis. The company's flagship product in development is Neffy, a needle-free, low-dose intranasal epinephrine nasal spray designed to offer a safe, effective, and user-friendly alternative to traditional injectable epinephrine devices. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
SPRY
Country
🇺🇸 United States